Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCGO-RCT).

Details

Ressource 1Download: BMJ_e040117.full.pdf (544.21 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_B8E00400B6EE
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCGO-RCT).
Journal
BMJ open
Author(s)
Clair C., Augsburger A., Birrer P., Locatelli I., Schwarz J., Greub G., Zanchi A., Jacot-Sadowski I., Puder J.J.
ISSN
2044-6055 (Electronic)
ISSN-L
2044-6055
Publication state
Published
Issued date
19/11/2020
Peer-reviewed
Oui
Volume
10
Number
11
Pages
e040117
Language
english
Notes
Publication types: Clinical Trial Protocol ; Journal Article
Publication Status: epublish
Abstract
Few studies have assessed the efficacy of smoking cessation interventions in individuals with type 2 diabetes, but interventions adapted to the specific needs of this population are warranted. The aim of this study is to assess the efficacy of a smoking cessation intervention in a population of smokers with type 2 diabetes and to measure the metabolic impact of smoking cessation.
The study is an open-label, randomised control trial. Participants recruited from a sanitary region of Switzerland will be randomly allocated to either the intervention or the control arm. The intervention group will have four individual counselling sessions over 12 weeks. Trained research nurses will conduct the behavioural intervention, using motivational interviews and addressing diabetes and gender specificities. The control group will have one short counselling session at baseline and will be given written information on smoking cessation. Both groups will have a follow-up visit at 26 and 52 weeks. Demographic and medical data will be collected at baseline and follow-up, along with blood and urine samples. The primary study outcome is continuous smoking abstinence validated by expired-air carbon monoxide from week 12 to week 52. Secondary study outcomes are continuous and 7-day point prevalence smoking abstinence at 12 and 26 weeks; change in motivation to quit and cigarette consumption; and change in glycosylated haemoglobin levels, body weight, waist circumference and renal function after smoking cessation. In a subsample of 80 participants, change in stool microbiota from baseline will be measured at 3, 8 and 26 weeks after smoking cessation.
Ethical approval has been obtained by the competent ethics committee (Commission cantonale d'éthique de la recherche sur l'être humain, CER-VD 2017-00812). The results of the study will be disseminated through publications in peer-reviewed journals and conference presentations.
ClinicalTrials.gov NCT03426423 and SNCTP000002762; Pre-results.
Keywords
Adolescent, Behavior Therapy, Diabetes Mellitus, Type 2/therapy, Female, Humans, Male, Pregnancy, Randomized Controlled Trials as Topic, Smokers, Smoking Cessation, Switzerland, diabetes & endocrinology, general medicine (see internal medicine), preventive medicine
Pubmed
Web of science
Open Access
Yes
Create date
26/01/2021 14:40
Last modification date
05/06/2021 5:33
Usage data